Catabasis Pharma (CATB) – Press Releases
-
Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus
-
Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
-
Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference
-
Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference
-
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
-
Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update
-
Xontogeny Announces Launch of Several New Early-Stage Portfolio Companies
-
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
-
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
-
Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.
-
Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
-
Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy
-
Catabasis Pharmaceuticals Presents Information on Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy, at the Virtual 25th International Congress of the World Muscle Societ
-
Catabasis Pharmaceuticals to Present During the Virtual 25th International Congress of the World Muscle Society
-
Catabasis Pharmaceuticals Names Noah Clauser Chief Financial Officer
-
Catabasis Pharmaceuticals to Host Virtual KOL Event on Edasalonexent and Duchenne Muscular Dystrophy
-
Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progress
-
Catabasis Pharmaceuticals to Present at Virtual 2020 Wedbush PacGrow Healthcare Conference
-
Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis
-
Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th
-
Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference
-
Catabasis Joins Russell 3000® Index
-
Catabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General Counsel
-
Catabasis Pharmaceuticals Reports First Quarter 2020 Financial Results and Reviews Business Progress
-
Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy
-
Catabasis Pharmaceuticals to Report First Quarter 2020 Financial Results on Tuesday, May 12th
-
Catabasis Pharmaceuticals to Present at 2020 Muscular Dystrophy Association Virtual Poster Session
-
Catabasis Pharmaceuticals to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference
-
Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
-
Catabasis Pharmaceuticals to Present During the Muscular Dystrophy Association Virtual Clinical Trials Session
-
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Reviews Business Progress
-
Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments on Tuesday, March 10th
-
Catabasis Pharmaceuticals to Present Edasalonexent at the XVIII International Conference on Duchenne and Becker Muscular Dystrophy
-
Catabasis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option
-
Catabasis Pharmaceuticals Announces Pricing of $23 Million Underwritten Public Offering
-
Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering
-
Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial
-
Catabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial Enrolled Expected Patient Population
-
Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business Progress
-
Catabasis Pharmaceuticals to Present Third Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, November 7th
-
Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting
-
Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy
-
Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment
-
Catabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle Society
-
Catabasis Pharmaceuticals and the Jain Foundation Announce a Preclinical Research Collaboration to Study Edasalonexent in Dysferlinopathy
-
Catabasis Pharmaceuticals Names Andrew A. Komjathy Chief Commercial Officer
-
Catabasis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Reviews Business Progress
-
Catabasis Pharmaceuticals Appoints Hugh M. Cole to its Board of Directors
-
Catabasis Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference
-
Catabasis Pharmaceuticals to Report Second Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, August 8th
Back to CATB Stock Lookup
